Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres

Mark A Samaan, Polychronis Pavlidis, Emma Johnston, Ben Warner, Jonathan Digby-Bell, Ioannis Koumoutsos, Steven Fong, Rimma Goldberg, Kamal Patel, Shraddha Gulati, Lucy Medcalf, Marlene Sastrillo, Cordella Brown-Clarke, Johanna Bidewell-Sullivan, Katrina Forsyth, Emma Lee, Anna Stanton, Julie Duncan, Guy Chung-Faye, Patrick DuboisNick Powell, Simon Anderson, Jeremy Sanderson, Bu'Hussain Hayee, Peter M Irving

Research output: Contribution to journalArticlepeer-review

34 Citations (Scopus)


OBJECTIVE: To gain an understanding of the efficacy of vedolizumab in a 'real-world' setting.

DESIGN: Retrospective cohort study using prospectively maintained clinical records.

SETTING: Two UK tertiary inflammatory bowel disease (IBD) centres.

PATIENTS: Patients with IBD commenced on vedolizumab at Guy's & St Thomas' and King's College Hospitals during November 2014-November 2015.

INTERVENTION: Vedolizumab, a monoclonal antibody to α-4 β-7 integrins that selectively inhibit leucocyte migration into the gut.

MAIN OUTCOME MEASURES: Clinical disease activity was assessed at baseline, weeks 14 and 30 using Harvey-Bradshaw Index (HBI) for Crohn's disease (CD) and Simple Clinical Colitis Activity Index (SCCAI) for ulcerative colitis (UC). Response was defined as HBI or SCCAI reduction ≥3. Remission was defined as HBI <5 or SCCAI <3. Continuous data are summarised as medians, followed by range.

RESULTS: Fifty patients were included: 27 CD, 20 UC and 3 IBD-U (included in the UC group for analysis). At baseline visit, the median HBI was 8 (1-16) and SCCAI was 6 (0-15). At week 14, these values had fallen to 5 (0-15) (p=0.117) and 4 (0-10) (p=0.005), respectively. Additionally, week 30 data were available for 19 patients (9 CD, 10 UC). The clinical disease activity scores at that point were HBI 2 (0-7) (p=0.039) and SCCAI 2 (0-10) (p=0.023). At baseline, 37 (74%) of the 50 patients had clinically active disease. Of the patients with active disease, 22 (59%) responded and 14 (38%) achieved remission at week 14.

CONCLUSIONS: Our early experience with vedolizumab demonstrates a clear benefit in terms of disease control as well as a steroid-sparing effect in a cohort, which included patients with complex and previously refractory disease.

Original languageEnglish
Pages (from-to)196-202
Number of pages7
JournalFrontline Gastroenterology
Issue number3
Publication statusPublished - Jul 2017


Dive into the research topics of 'Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centres'. Together they form a unique fingerprint.

Cite this